Global Longevity & Anti-Senescence Therapy Market Review 2017-2018 and Forecast to 2023 – ResearchAndMarkets.com – Business Wire

DUBLIN--(BUSINESS WIRE)--The "Global Longevity and Anti-Senescence Therapy Market" report has been added to ResearchAndMarkets.com's offering.

Global longevity and anti-senescence market will witness rapid growth over the forecast period (2018-2023) owing to an increasing emphasis on Stem Cell Research and increasing demand for cell-based assays in research and development.

An increasing geriatric population across the globe and rising awareness of antiaging products among generation Y and later generations are the major factors expected to promote the growth of global longevity and anti-senescence market. Factors such as a surging level of disposable income and increasing advancements in anti-senescence technologies are also providing traction to the global longevity and anti-senescence market growth over the forecast period (2018-2023).

Senolytics, placenta stem cells and blood transfusions are some of the hot technologies picking up pace in the longevity and anti-anti-senescence market. Companies and start-ups across the globe such as Unity Biotechnology, Human Longevity Inc., Calico Life Sciences, Acorda Therapeutics, etc. are working extensively in this field for the extension of human longevity by focusing on the study of genomics, microbiome, bioinformatics, and stem cell therapies, etc. These factors are poised to drive market growth over the forecast period.

The report provides analysis based on each market segment including therapies and application. The therapies segment is further sub-segmented into Senolytic drug therapy, Gene therapy, Immunotherapy, and Others. Senolytic drug therapy held the largest market revenue share in 2017. The fastest growth of the gene therapy segment is due to the Large investments in genomics.

Report Scope

The scope of this report is broad and covers various therapies currently under trials in the global longevity and anti-senescence therapy market. The market estimation has been performed with consideration for revenue generation in the forecast years 2018-2023 after the expected availability of products in the market by 2023.

The global longevity and anti-senescence therapy market has been segmented by the following therapies: Senolytic drug therapy, Gene therapy, Immunotherapy and Other therapies which includes stem cell-based therapies, etc.

Revenue forecasts from 2028 to 2023 are given for each therapy and application, with estimated values derived from the expected revenue generation in the first year of launch.

The report also includes a discussion of the major players performing research or the potential players across each regional longevity and anti-senescence therapy market. Further, it explains the major drivers and regional dynamics of the global longevity and anti-senescence therapy market and current trends within the industry.

The report concludes with a special focus on the vendor landscape and includes detailed profiles of the major vendors and potential entrants in the global longevity and anti-senescence therapy market.

The report includes:

Key Topics Covered

Chapter 1 Introduction

Chapter 2 Summary and Highlights

Chapter 3 Market Overview

Chapter 4 Global Longevity and Anti-senescence Market by Therapy

Chapter 5 Global Longevity and Anti-senescence Market by Application

Chapter 6 Global Longevity and Anti-senescence Market by Region

Chapter 7 Industry Structure in Longevity and Anti-senescence Market

Chapter 8 Company Profiles

For more information about this report visit https://www.researchandmarkets.com/r/zy7jt

More:

Global Longevity & Anti-Senescence Therapy Market Review 2017-2018 and Forecast to 2023 - ResearchAndMarkets.com - Business Wire

LyGenesis Closes $4 Million Convertible Debt Financing to Begin Clinical Development of its Liver Regeneration Technology – PRNewswire

PITTSBURGH, Oct. 21, 2019 /PRNewswire/ -- LyGenesis, Inc., a biotechnology company focused on organ regeneration, announced today that they have completed a total of $4 million in private financing of convertible notes from Juvenescence, Ltd. and Longevity Vision Fund. Their technology uses lymph nodes as bioreactors to regrow functioning organs within a patient's own body. This financing will enable LyGenesis's lead program in liver regeneration to transition into clinical development, beginning with a Phase 2a clinical trial for patients with end stage liver disease in 2020.

"We have advanced our liver regeneration program through preclinical trials and this financing will help us to rapidly transition into a clinical-stage biotechnology company," said Michael Hufford, PhD, Co-Founder and CEO of LyGenesis. "Our ability to use the lymph node as a bioreactor for organogenesis is also generating interest from partner companies looking for an enabling technology so that their genetically modified cell therapies are able to engraft, proliferate, vascularize, and produce a therapeutic effect in patients."

"We are thrilled to continue our financial support of LyGenesis as they transition into clinical development," said Greg Bailey, MD, Co-Founder and CEO of Juvenescence, and a member of LyGenesis's Board of Directors. Sergey Young, founder of Longevity Vision Fund, said "The ability to regenerate functioning ectopic organs was science fiction just a few short years ago. The progress of LyGenesis's technology is emblematic of the rapid advances we are witnessing as biotechnology transitions from bench research, to preclinical models, and now into the clinic."

About LyGenesis, Inc.LyGenesis is a biotechnology company with an organ regeneration technology platform enabling a patient's lymph nodes to be used as bioreactors to regrow functioning ectopic organs. LyGenesis's lead allogeneic cell therapy program is focused on liver regeneration for patients with end stage liver disease. Its drug development pipeline includes thymus, pancreas, and kidney regeneration. Privately held, LyGenesis is headquartered in Pittsburgh, Pennsylvania. To learn more, please visit lygenesis.com.

About Juvenescence, Ltd.Juvenescence Limited is a life sciences company developing therapies to increase healthy human longevity. It was founded by Jim Mellon, Dr. Greg Bailey and Dr. Declan Doogan. The Juvenescence team are highly experienced drug developers, entrepreneurs and investors with a significant history of success in the life sciences sector. Juvenescence will create, partner with or invest in new companies with longevity-related therapeutics, by in-licensing compounds from academia and industry, or forming joint ventures to develop therapeutics for longevity. Juvenescence believes that recent advances in science have greatly improved our understanding of the biology of aging and seeks to develop therapeutics with the possibility of slowing, halting or potentially reversing elements of aging. To learn more, please visit juvenescence.ltd.

About Longevity Vision FundLongevity Vision Fundis a $100M life extension-focused investment fund dedicated to making longevity affordable and accessible to all. Founded by Sergey Young, the fund accelerates breakthroughs in longevity by investing in start-ups and companies that develop technologies, products, and services that extend human lifespans and overcome the negative effects of aging. The Fund provides funding to biotech and life extension-focused companies developing early diagnostics, AI in healthcare, and therapies addressing age-related diseases. To learn more, please visit lvf.vc.

Media Contact:Michael Hufford, PhD+1.858.603.2514226496@email4pr.com

SOURCE LyGenesis, Inc.

http://www.lygenesis.com

See more here:

LyGenesis Closes $4 Million Convertible Debt Financing to Begin Clinical Development of its Liver Regeneration Technology - PRNewswire

Chinese Longitudinal Healthy Longevity Survey (CLHLS …

WELCOME! The Chinese Longitudinal Healthy Longevity Survey (CLHLS) has been supported by NIA/NIH grants R01 AG023627-01 (PI: Zeng Yi) (Grant name: Demographic Analysis of Healthy Longevity in China) and P01 AG 008761 (PI: Zeng Yi; Program Project Director: James W. Vaupel), awarded to Duke University, with Chinese matching support for personnel costs and some local expenses. UNFPA and the China Social Sciences Foundation provided additional support for expanding the 2002 CLHLS survey. The Max Planck Institute for Demographic Research has provided support for international training since the CLHLS 1998 baseline survey. Finally, in December 2004 the China Natural Sciences Foundation and the Hong Kong Research Grants Council (RGC) partnered with NIA/NIH, providing grants to partially support the CLHLS project.

Until present, the CLHLS conducted face-to-face interviews with 8,959, 11,161, 20,428, 18,549 and 20,366, 10,188, and 7,192individuals in 1998, 2000, 2002, 2005, 2008-09, 2011-12, and 2014, respectively, using internationally compatible questionnaires. Among the 96,843interviews conducted in the sevenwaves, 16,547were with centenarians, 22,232with nonagenarians, 25,719with octogenarians, 19,884with younger elders aged 65-79, and 11,461 with middle-age adults aged 35-64. At each wave, survivors were re-interviewed, and deceased interviewees were replaced with new participants. Data on mortality and health status before dying for the 26,236elders aged 65-110 who died between waves were collected in interviews with a close family member of the deceased.

The CLHLS has the largest sample of centenarians in the world according to a report in Science (see the report). Our general goal is to shed new light on a better understanding of the determinants of healthy longevity of human beings. We are compiling extensive data on a much larger population of the oldest-old aged 80-112 than has previously been studied, with a comparison group of younger elders aged 65-79. We propose to use innovative demographic and statistical methods to analyze longitudinal survey data. Our goal is to determine which factors, out of a large set of social, behavioral, biological, and environmental risk factors, play an important role in healthy longevity. The large population size, the focus on healthy longevity (rather than on a specific disease or disorder), the simultaneous consideration of various risk factors, and the use of analytical strategies based on demographic concepts make this an innovative demographic data collection and research project.

Our specific objectives are as follows:

The organizational framework of the CLHLS is summarized as follows:

See the original post:

Chinese Longitudinal Healthy Longevity Survey (CLHLS ...

Opinion: Entrepreneurs and Their Startup Businesses Need San Diegos Support – Times of San Diego

Share This Article:Startup teams at an EvoNesus incubator in downtown San Diego. Photo by Chris JenneweinBy Duane Cameron

Everyone in business and economic development agree that startups are great for citiesbut how can communities and leaders do more than just tout the benefits of startups, and actually help pave the way for entrepreneurs to bring their business ideas to life?

Support Times of San Diego's growthwith a small monthly contribution

One way of getting behind San Diego startups is through celebrating the innovation and creativity being brought to our region. This month Cox Business, Tech Coast Angels and the San Diego Venture Group are doing exactly that by sponsoring and organizing the John G. Watson Quick Pitch Competition.

The Quick Pitch Competition on Oct. 29 gives 10 local startups the opportunity to compete for grants of up to $50,000 to further develop their idea. Its one of several others like it throughout the year here in our region.

However, we can always do more to support our startup ecosystemespecially if we want to hang on to our distinction as one of the best cities in America to launch a business. Moreover, San Diego in particular has a number of very good reasons to do so:

Small businesses, including startups, are the backbone of our regional economy. Small businesses, defined as those with 100 employees or fewer, employ697,000 people, or 59 percentof San Diegos workforce. If we were to attract fewer talented entrepreneurs, opportunities for both our long-time residents and recent transplants would dry up, and our economy would suffer.

Theyve given us our reputation as a life sciences and biotechnology innovation hub. Aside from the San Francisco Bay Area and the Boston-Cambridge region, were one of the top cities for manufacturing, testing and research in the fields of biotechnology, pharmaceuticals and medical devices. Several of the top employers in this area are, of course, large companies like Illumina, but a vast majority of the more than 1,100 life and sciences biotech businesses in San Diego began life as small startups with an idea.

They encourage competition. Competition is a good thing and spurs innovation, and a competitive business ecosystem makes our city stand out as a dynamic source of tech solutions. As Ben Yoskowitz, an angel investor and founding partner at Year One Labs puts it, Any reasonably good idea has 10,000 people working on it right now.

A few local startups have made it big already. Thanks to our large pool of talent both local and transplanted (the perks of being a major center for universities) as well as a good network of accelerators that coach startups on how to prepare for a successful launch, many of our startups have emerged as major players on the national scene. Think GoFundMe, Classy, Brain Corp, and Human Longevity. Imagine how many more ideas like these are currently incubating among San Diegos startup founders.

They employ talent from other tech hubs, especially recent graduates. The job market may have improved greatly since the 2008-2009 recession, and unemployment may be low, but its still challenging to get your foot in the door as a recent college graduate. In cities like San Diego, though, where theres a strong pool of startups, these young professionals can easily find employment that develops them professionally into the future talent that our city will need to continue to grow.

San Diego has steadily climbed higher on lists of top U.S. cities for startups over the past few years, but that didnt happen in a vacuum. Every big company started small, and its important that larger companies encourage startups, and help provide funding through programs such as the Quick Pitch Competitionespecially if theyre in your field. Its good for business and for everyone who lives and works in Americas finest region.

Duane Cameron has more than 30 years of experience in the telecommunications industry. He is vice president for Cox Business, helping to bring innovative products and services to Southern California businesses.

Opinion: Entrepreneurs and Their Startup Businesses Need San Diegos Support was last modified: October 17th, 2019 by Editor

>> Subscribe to Times of San Diegos free daily email newsletter! Click here

Read the rest here:

Opinion: Entrepreneurs and Their Startup Businesses Need San Diegos Support - Times of San Diego

Careers Human Longevity, Inc.

Human Longevity, Inc., is a rapidly growing company founded by visionary scientists, innovators, and entrepreneurs to revolutionize the practice of medicine by using genomics and technology to make healthcare more personalized. We have built and continue to expand the worlds largest database of genotype, phenotype and clinical information that with a proprietary data mining infrastructure generates health intelligence to illuminate new ways to predict, prevent, and treat some of the worlds foremost health threats like cancer, heart disease, and diabetes.

Founded by renowned scientist J. Craig Venter, Ph.D., Human Longevity, Inc., and its clinical research center, the Health Nucleus, are blazing new trails in science, medicine, and research and we need people who, like us, want to change the world. We are leading the way in learning tools, cloud technology, and sequencing operations, and are looking for individuals to join with us in developing these new innovations.

If you are dynamic, innovative, curious, resourceful and want to be a part of revolutionizing healthcare, HLI is the place for you.

Human Longevity, Inc., offers a comprehensive Total Rewards program, enabling you to focus on revolutionizing healthcare:

To view opportunities to make your mark at HLI, click below.

HLI PARTICIPATES IN E-VERIFY

HLI will provide the Social Security Administration (SSA) and, if necessary, the Department of Homeland Security (DHS), with information from each new employees Form I-9 to confirm work authorization. Human Longevity, Inc., is an equal opportunity employer.

Jump to Open Positions

More:

Careers Human Longevity, Inc.

Is longevity determined by genetics? – Genetics Home …

The duration of human life (longevity) is influenced by genetics, the environment, and lifestyle. Environmental improvements beginning in the 1900s extended the average life span dramatically with significant improvements in the availability of food and clean water, better housing and living conditions, reduced exposure to infectious diseases, and access to medical care. Most significant were public health advances that reduced premature death by decreasing the risk of infant mortality, increasing the chances of surviving childhood, and avoiding infection and communicable disease. Now people in the United States live about 80 years on average, but some individuals survive for much longer.

Scientists are studying people in their nineties (called nonagenarians) and hundreds (called centenarians, including semi-supercentenarians of ages 105-109 years and supercentenarians, ages 110+) to determine what contributes to their long lives. They have found that long-lived individuals have little in common with one another in education, income, or profession. The similarities they do share, however, reflect their lifestylesmany are nonsmokers, are not obese, and cope well with stress. Also, most are women. Because of their healthy habits, these older adults are less likely to develop age-related chronic diseases, such as high blood pressure, heart disease, cancer, and diabetes, than their same-age peers.

The siblings and children (collectively called first-degree relatives) of long-lived individuals are more likely to remain healthy longer and to live to an older age than their peers. People with centenarian parents are less likely at age 70 to have the age-related diseases that are common among older adults. The brothers and sisters of centenarians typically have long lives, and if they develop age-related diseases (such as high blood pressure, heart disease, cancer, or type 2 diabetes), these diseases appear later than they do in the general population. Longer life spans tend to run in families, which suggests that shared genetics, lifestyle, or both play an important role in determining longevity.

The study of longevity genes is a developing science. It is estimated that about 25 percent of the variation in human life span is determined by genetics, but which genes, and how they contribute to longevity, are not well understood. A few of the common variations (called polymorphisms) associated with long life spans are found in the APOE, FOXO3, and CETP genes, but they are not found in all individuals with exceptional longevity. It is likely that variants in multiple genes, some of which are unidentified, act together to contribute to a long life.

Whole genome sequencing studies of supercentenarians have identified the same gene variants that increase disease risk in people who have average life spans. The supercentenarians, however, also have many other newly identified gene variants that possibly promote longevity. Scientists speculate that for the first seven or eight decades, lifestyle is a stronger determinant of health and life span than genetics. Eating well, not drinking too much alcohol, avoiding tobacco, and staying physically active enable some individuals to attain a healthy old age; genetics then appears to play a progressively important role in keeping individuals healthy as they age into their eighties and beyond. Many nonagenarians and centenarians are able to live independently and avoid age-related diseases until the very last years of their lives.

Some of the gene variants that contribute to a long life are involved with the basic maintenance and function of the bodys cells. These cellular functions include DNA repair, maintenance of the ends of chromosomes (regions called telomeres), and protection of cells from damage caused by unstable oxygen-containing molecules (free radicals). Other genes that are associated with blood fat (lipid) levels, inflammation, and the cardiovascular and immune systems contribute significantly to longevity because they reduce the risk of heart disease (the main cause of death in older people), stroke, and insulin resistance.

In addition to studying the very old in the United States, scientists are also studying a handful of communities in other parts of the world where people often live into their nineties and olderOkinawa (Japan), Ikaria (Greece), and Sardinia (Italy). These three regions are similar in that they are relatively isolated from the broader population in their countries, are lower income, have little industrialization, and tend to follow a traditional (non-Western) lifestyle. Unlike other populations of the very old, the centenarians on Sardinia include a significant proportion of men. Researchers are studying whether hormones, sex-specific genes, or other factors may contribute to longer lives among men as well as women on this island.

Martin GM, Bergman A, Barzilai N. Genetic determinants of human health span and life span: progress and new opportunities. PLoS Genet. 2007 Jul;3(7):e125. PubMed: 17677003. Free full-text available from PubMed Central: PMC1934400.

Sebastiani P, Gurinovich A, Bae H, Andersen S, Malovini A, Atzmon G, Villa F, Kraja AT, Ben-Avraham D, Barzilai N, Puca A, Perls TT. Four genome-wide association studies identify new extreme longevity variants. J Gerontol A Biol Sci Med Sci. 2017 Oct 12;72(11):1453-1464. doi: 10.1093/gerona/glx027. PubMed: 28329165.

Sebastiani P, Solovieff N, Dewan AT, Walsh KM, Puca A, Hartley SW, Melista E, Andersen S, Dworkis DA, Wilk JB, Myers RH, Steinberg MH, Montano M, Baldwin CT, Hoh J, Perls TT. Genetic signatures of exceptional longevity in humans. PLoS One. 2012;7(1):e29848. doi: 10.1371/journal.pone.0029848. Epub 2012 Jan 18. PubMed: 22279548. Free full-text available from PubMed Central: PMC3261167.

Wei M, Brandhorst S, Shelehchi M, Mirzaei H, Cheng CW, Budniak J, Groshen S, Mack WJ, Guen E, Di Biase S, Cohen P, Morgan TE, Dorff T, Hong K, Michalsen A, Laviano A, Longo VD. Fasting-mimicking diet and markers/risk factors for aging, diabetes, cancer, and cardiovascular disease. Sci Transl Med. 2017 Feb 15;9(377). pii: eaai8700. doi: 10.1126/scitranslmed.aai8700. PubMed: 28202779.

Young RD. Validated living worldwide supercentenarians, living and recently deceased: February 2018. Rejuvenation Res. 2018 Feb 1. doi: 10.1089/rej.2018.2057. [Epub ahead of print] PubMed: 29390945.

Read the original post:

Is longevity determined by genetics? - Genetics Home ...

Offer Ends Soon Ready Version – The Human Longevity Project

The Human Longevity Project is a 9-Part documentary with over 100 interviews from the worlds leading doctors, researchers, scientists, health experts, and healers.

We combine the most cutting-edge science with a deep investigation into the worlds healthiest and oldest populations.

This program gives you a detailed roadmap and step-by-step action plan for you to live your longest, happiest, and healthiest life.

Included are detailed interviews with the worlds healthiest and longest-lived people, a large number of whom are happy centenarians, tapping into powerful ancient wisdom for optimal health, wellbeing and maximum longevity!

Whether you or your loved ones have a chronic illness like depression, autoimmune disease, digestive issues

Or maybe its Diabetes, Heart Disease, Autism or Alzheimer's

Never before have so many doctors, researchers, scientists, health experts, and the healthiest populations on Earth come together to create this educational masterpiece, showing you solutions that can be implemented to avoid pain and disease in your life, and start accessing the SECRET, MODERN and ANCIENT remedies for You and Your familys Optimal Healing and Lifespan.

Dont delay get your personal copy today. Once The Human Longevity Project premiere is overyou'll never see this offer again! Prices will more than DOUBLE at the end of the premiere!

REMEMBER This offer is only available here during The Human Longevity Project World Premiere! Once this series is over, this offer will be gone FOR GOOD.

Original post:

Offer Ends Soon Ready Version - The Human Longevity Project

Human Longevity – Wikipedia

Human Longevity is a San Diego-based venture launched by Craig Venter and Peter Diamandis in 2013. Its goal is to build the world's most comprehensive database on human genotypes and phenotypes, and then subject it to machine learning so that it can help develop new ways to fight diseases associated with aging.[1] The company received US$80 million in investments in its Series A offering in summer 2014 and announced a further $220 million Series B investment offering in April 2016.[2] It has made deals with drug companies Celgene and AstraZeneca to collaborate in its research.

While it is conducting research, the company is offering a wellness service known as "Health Nucleus," which offers customers a range of medical tests such as a full genome sequencing and tests for early indications of cancers, Alzheimer's and heart disease.[3] This testing is meant to help people catch diseases earlier than otherwise possible and to identify risk factors for diseases later in life.[4]

At the start of 2017 the company hired Cynthia Collins from GE Healthcare, and Venter became Executive Chair. The company's chief operating office, Mark Winham, left the company in mid-2017, and Collins and the company's chief medical officer, Brad Perkins, left in December. Venter stepped back into the CEO role, but announced in May 2018 that he was leaving the company to return to the J. Craig Venter Institute.[5] Venter was sued for allegedly 'stealing trade secrets' at Human Longevity.[6] The case has been dismissed.[7]

Read more from the original source:

Human Longevity - Wikipedia

Longevity – Wikipedia

The word "longevity" is sometimes used as a synonym for "life expectancy" in demography. However, the term longevity is sometimes meant to refer only to especially long-lived members of a population, whereas life expectancy is always defined statistically as the average number of years remaining at a given age. For example, a population's life expectancy at birth is the same as the average age at death for all people born in the same year (in the case of cohorts). Longevity is best thought of as a term for general audiences meaning 'typical length of life' and specific statistical definitions should be clarified when necessary.

Reflections on longevity have usually gone beyond acknowledging the brevity of human life and have included thinking about methods to extend life. Longevity has been a topic not only for the scientific community but also for writers of travel, science fiction, and utopian novels.

There are many difficulties in authenticating the longest human life span ever by modern verification standards, owing to inaccurate or incomplete birth statistics. Fiction, legend, and folklore have proposed or claimed life spans in the past or future vastly longer than those verified by modern standards, and longevity narratives and unverified longevity claims frequently speak of their existence in the present.

A life annuity is a form of longevity insurance.

Various factors contribute to an individual's longevity. Significant factors in life expectancy include gender, genetics, access to health care, hygiene, diet and nutrition, exercise, lifestyle, and crime rates. Below is a list of life expectancies in different types of countries:[3]

Population longevities are increasing as life expectancies around the world grow:[1][4]

The Gerontology Research Group validates current longevity records by modern standards, and maintains a list of supercentenarians; many other unvalidated longevity claims exist. Record-holding individuals include:[5][6][7]

Evidence-based studies indicate that longevity is based on two major factors, genetics and lifestyle choices.[9]

Twin studies have estimated that approximately 20-30% the variation in human lifespan can be related to genetics, with the rest due to individual behaviors and environmental factors which can be modified.[10] Although over 200 gene variants have been associated with longevity according to a US-Belgian-UK research database of human genetic variants,[11] these explain only a small fraction of the heritability.[12] A 2012 study found that even modest amounts of leisure time physical exercise can extend life expectancy by as much as 4.5 years.[13]

Lymphoblastoid cell lines established from blood samples of centenarians have significantly higher activity of the DNA repair protein PARP (Poly ADP ribose polymerase) than cell lines from younger (20 to 70 year old) individuals.[14] The lymphocytic cells of centenarians have characteristics typical of cells from young people, both in their capability of priming the mechanism of repair after H2O2 sublethal oxidative DNA damage and in their PARP gene expression.[15] These findings suggest that elevated PARP gene expression contributes to the longevity of centenarians, consistent with the DNA damage theory of aging.[16]

In preindustrial times, deaths at young and middle age were more common than they are today. This is not due to genetics, but because of environmental factors such as disease, accidents, and malnutrition, especially since the former were not generally treatable with pre-20th-century medicine. Deaths from childbirth were common for women, and many children did not live past infancy. In addition, most people who did attain old age were likely to die quickly from the above-mentioned untreatable health problems. Despite this, there are many examples of pre-20th-century individuals attaining lifespans of 85 years or greater, including Benjamin Franklin, Thomas Jefferson, John Adams, Cato the Elder, Thomas Hobbes, Eric of Pomerania, Christopher Polhem, and Michelangelo. This was also true for poorer people like peasants or laborers. Genealogists will almost certainly find ancestors living to their 70s, 80s and even 90s several hundred years ago.

For example, an 1871 census in the UK (the first of its kind, but personal data from other censuses dates back to 1841 and numerical data back to 1801) found the average male life expectancy as being 44, but if infant mortality is subtracted, males who lived to adulthood averaged 75 years. The present life expectancy in the UK is 77 years for males and 81 for females, while the United States averages 74 for males and 80 for females.

Studies have shown that black American males have the shortest lifespans of any group of people in the US, averaging only 69 years (Asian-American females average the longest).[17] This reflects overall poorer health and greater prevalence of heart disease, obesity, diabetes, and cancer among black American men.

Women normally outlive men. Theories for this include smaller bodies (and thus less stress on the heart), a stronger immune system (since testosterone acts as an immunosuppressant), and less tendency to engage in physically dangerous activities.

There is debate as to whether the pursuit of longevity is a worthwhile health care goal. Bioethicist Ezekiel Emanuel, who is also one of the architects of ObamaCare, has argued that the pursuit of longevity via the compression of morbidity explanation is a "fantasy" and that longevity past age 75 should not be considered an end in itself.[18] This has been challenged by neurosurgeon Miguel Faria, who states that life can be worthwhile in healthy old age, that the compression of morbidity is a real phenomenon, and that longevity should be pursued in association with quality of life.[19] Faria has discussed how longevity in association with leading healthy lifestyles can lead to the postponement of senescence as well as happiness and wisdom in old age.[20]

All of the biological organisms have a limited longevity, and different species of animals and plants have different potentials of longevity. Misrepair-accumulation aging theory [21][22] suggests that the potential of longevity of an organism is related to its structural complexity.[23] Limited longevity is due to the limited structural complexity of the organism. If a species of organisms has too high structural complexity, most of its individuals would die before the reproduction age, and the species could not survive. This theory suggests that limited structural complexity and limited longevity are essential for the survival of a species.

Longevity myths are traditions about long-lived people (generally supercentenarians), either as individuals or groups of people, and practices that have been believed to confer longevity, but for which scientific evidence does not support the ages claimed or the reasons for the claims.[24][25] A comparison and contrast of "longevity in antiquity" (such as the Sumerian King List, the genealogies of Genesis, and the Persian Shahnameh) with "longevity in historical times" (common-era cases through twentieth-century news reports) is elaborated in detail in Lucian Boia's 2004 book Forever Young: A Cultural History of Longevity from Antiquity to the Present and other sources.[26]

After the death of Juan Ponce de Len, Gonzalo Fernndez de Oviedo y Valds wrote in Historia General y Natural de las Indias (1535) that Ponce de Len was looking for the waters of Bimini to cure his aging.[27] Traditions that have been believed to confer greater human longevity also include alchemy,[28] such as that attributed to Nicolas Flamel. In the modern era, the Okinawa diet has some reputation of linkage to exceptionally high ages.[29]

Longevity claims may be subcategorized into four groups: "In late life, very old people often tend to advance their ages at the rate of about 17 years per decade .... Several celebrated super-centenarians (over 110 years) are believed to have been double lives (father and son, relations with the same names or successive bearers of a title) .... A number of instances have been commercially sponsored, while a fourth category of recent claims are those made for political ends ...."[30] The estimate of 17 years per decade was corroborated by the 1901 and 1911 British censuses.[30] Time magazine considered that, by the Soviet Union, longevity had been elevated to a state-supported "Methuselah cult".[31] Robert Ripley regularly reported supercentenarian claims in Ripley's Believe It or Not!, usually citing his own reputation as a fact-checker to claim reliability.[32]

The U.S. Census Bureau view on the future of longevity is that life expectancy in the United States will be in the mid-80s by 2050 (up from 77.85 in 2006) and will top out eventually in the low 90s, barring major scientific advances that can change the rate of human aging itself, as opposed to merely treating the effects of aging as is done today. The Census Bureau also predicted that the United States would have 5.3 million people aged over 100 in 2100. The United Nations has also made projections far out into the future, up to 2300, at which point it projects that life expectancies in most developed countries will be between 100 and 106 years and still rising, though more and more slowly than before. These projections also suggest that life expectancies in poor countries will still be less than those in rich countries in 2300, in some cases by as much as 20 years. The UN itself mentioned that gaps in life expectancy so far in the future may well not exist, especially since the exchange of technology between rich and poor countries and the industrialization and development of poor countries may cause their life expectancies to converge fully with those of rich countries long before that point, similarly to the way life expectancies between rich and poor countries have already been converging over the last 60 years as better medicine, technology, and living conditions became accessible to many people in poor countries. The UN has warned that these projections are uncertain, and cautions that any change or advancement in medical technology could invalidate such projections.[33]

Recent increases in the rates of lifestyle diseases, such as obesity, diabetes, hypertension, and heart disease, may eventually slow or reverse this trend toward increasing life expectancy in the developed world, but have not yet done so. The average age of the US population is getting higher[34] and these diseases show up in older people.[35]

Jennifer Couzin-Frankel examined how much mortality from various causes would have to drop in order to boost life expectancy and concluded that most of the past increases in life expectancy occurred because of improved survival rates for young people. She states that it seems unlikely that life expectancy at birth will ever exceed 85 years.[36] Michio Kaku argues that genetic engineering, nanotechnology and future breakthroughs will accelerate the rate of life expectancy increase indefinitely.[37] Already genetic engineering has allowed the life expectancy of certain primates to be doubled, and for human skin cells in labs to divide and live indefinitely without becoming cancerous.[38]

Reliable data from 1840 through 2002 indicates life expectancy has risen linearly for men and women, albeit more slowly for men. For women the increase has been almost three months per year, for men almost 2.7 months per year. In light of steady increase, without any sign of limitation, the suggestion that life expectancy will top out must be treated with caution. Scientists Oeppen and Vaupel observe that experts who assert that "life expectancy is approaching a ceiling ... have repeatedly been proven wrong." It is thought that life expectancy for women has increased more dramatically owing to the considerable advances in medicine related to childbirth.[39]

Currently living:

Non-living:

Read this article:

Longevity - Wikipedia